REVIEW

Scoping Review and Evidence Map of the Relation between Exposure to Dietary Sweetness and Body Weight-Related Outcomes in Adults

Kelly A Higgins,[1] Rita Rawal,[1] David J Baer,[1] Lauren E O'Connor,[1] and Katherine M Appleton[2]

[1] US Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Food Components and Health Laboratory, Beltsville, MD, USA; and [2] Bournemouth University, Department of Psychology, Bournemouth, UK

ABSTRACT

Numerous governmental and health organizations recommend reduced intake of added sugars due to the health risks associated with excess intake, including the risk of obesity. Some organizations further recommend avoiding dietary sweetness, regardless of the source. A scoping review and evidence map were completed to characterize the research that investigated associations between dietary sweetness and body weight. The aim was to identify and map published studies that have investigated total dietary sweetness, sweet food/beverages, sugar, or sweetener intake, and body weight–related outcomes and/or energy intake. Using preregistered search terms (osf.io/my7pb), 36,779 publications (duplicates removed) were identified from PubMed, Cochrane Library, and Scopus and screened for inclusion. Eligible studies were clinical trials, longitudinal cohorts, case–control studies, cross-sectional studies, and systematic reviews conducted among adults (age ≥18 y), which were performed to investigate associations between dietary sweetness, sweet foods/beverages, sugar, or sweetener (energetic or nonenergetic) intake and body weight, BMI, adiposity, and/or energy intake. A total of 833 eligible publications were identified, detailing 804 studies. Only 7 studies (0.9% of included studies; 2 clinical trials, 4 cross-sectional studies, and 1 with another design type) investigated associations between total dietary sweetness and body weight-related outcome and/or energy intake. An additional 608 (75.6%) studies investigated intakes of sweet foods/beverages, sugar, or sweetener, and body weight-related outcomes and/or energy intake, including 225 clinical trials, 81 longitudinal cohorts, 4 case–control studies, and 280 cross-sectional studies. Most studies (90.6%) did not measure the sweetness of the diet or individual foods consumed. Ninety-two (11.4%) publications reported data from studies on dietary patterns that included sweet foods/beverages alongside other dietary components and 97 (12.1%) systematic reviews addressed different but related research questions. Although there is a breadth of evidence from studies that have investigated associations between intakes of sweet foods and beverages, sugars, and sweeteners and body weight, there is a limited depth of evidence on the association between total dietary sweetness and body weight. *Adv Nutr* 2022;13:2341–2356.

Statement of Significance: Despite popular belief, there has been limited evidence published to date from investigations to determine if there is an association between dietary sweetness and body weight. The available evidence has been compiled for open access use for future investigations (osf.io/ckh9v/).

Keywords: body composition, ingestive behavior, sweetness, sweeteners, sugars, sensory, evidence map, scoping review

Introduction

Dietary recommendations from numerous governmental and public health organizations include reducing intake of added sugars [defined as "sugars that are either added during the processing of foods, or are packaged as such (e.g., a bag of sugar)"(1)] due to many health risks associated with excess sugar consumption (1–5), including an increased risk of overweight and obesity. Some public health organizations (including Health Canada and the Pan American Health Organization) also recommend avoiding dietary sweetness (6, 7) regardless of the source of the sweet taste [e.g., sugars, low-calorie sweeteners (LCS)] to facilitate reductions in sugar intake. The latter recommendation is based on the hypothesis that chronic and frequent exposure to dietary sweetness will increase the preference and desire for sweet foods/beverages, referred to colloquially as the development of a "sweet tooth" (7). A developed preference for sweetness may have negative implications for body weight (BW), due to the ease with

which excess energy from sources of sugar can be consumed in an ad libitum diet (8).

Despite the belief that heightened exposure to sweetness may lead to an increased preference or desire for sweet foods and beverages, there is no consensus as to whether the sweetness of the diet drives excess energy intake (EI) (9, 10). Changes to salt and fat preference in response to dietary manipulations have been observed in clinical trials (11, 12). While heightened sweetness perception was observed with reduced dietary sugar intake compared with a habitual diet in a 3-mo randomized controlled trial (RCT), no changes in preference for sweetness were observed (13). A systematic review designed to determine the association between sweet taste exposure and food acceptance, preference, and choice found that the available evidence from 21 studies (7 cohort studies and 14 controlled trials) was "very heterogeneous and does not provide clear, consistent support for a relation between sweet taste exposures and the outcomes considered" (9).

Whether or not dietary sweetness influences dietary preferences and EI has important implications for BW management. If exposure to sweetness has no effect on dietary preferences, then diets that enhance compliance to energy requirements, independent of level of sweetness, can be encouraged to facilitate weight maintenance. If reduced dietary sweetness (regardless of the source) leads to reduced preference for sweetness and results in reduced sweet food/beverage intake, then reduced dietary sweetness exposure may help facilitate BW management.

The uncertainty of the relation between dietary sweetness and BW is attributable in part to the many challenges associated with determining the sweetness of the entire diet. The human diet is complex and includes many foods and beverages with varying sensory properties that are consumed alone or in combination with other food components. Although the level of sugar and sweeteners within foods and perceived sweetness are correlated (14, 15), this relation is weakened by the presence of other components in the food matrix that can sequester sweeteners, physically preventing them from binding to the sweet taste receptor, or can centrally inhibit sweetness perception, such as the suppression of sweetness when a sweetener is consumed with a bitter compound (11). Quantifying intake of sweet foods/beverages, sugars, and sweeteners provides insufficient information for determining the sweetness of the entire diet, because intake of sweet foods/beverages at a given meal may result in compensation for other sources of sweetness in the diet. It is unclear to what degree compensation for sweetness at subsequent eating events occurs, though some research suggests at least partial compensation (16). Therefore, the type of sweetness exposure evaluated in a study (i.e., total dietary sweetness, sweet foods/beverages, sugar, or sweetener) has important implications for interpreting the results from these studies.

Before a conclusion on the association between dietary sweetness and BW can be determined, it is necessary to determine the availability of the evidence in the published literature. This scoping review and evidence map characterized the available evidence regarding the association between dietary sweetness and BW related outcomes and/or EI to help identify future research priorities. The primary aim was to identify and map studies that have investigated the association between total dietary sweetness and BW related outcomes and/or EI among healthy adults. The secondary aim was to identify and map the availability of reported studies that investigated sweet food/beverage, sugar, or sweetener intake and BW related outcomes and/or EI.

Methods

A scoping review is a systematic search of the literature to determine the number and characteristics of the studies on a particular topic (17). The resulting eligible evidence can be synthesized as an evidence map to identify patterns or future research needs (18, 19). The present review was conducted in accordance with the PRISMA extension for scoping reviews (20) (**Supplemental Checklist**) and the Joanna Briggs Institute scoping review framework (17). The methodology used in this scoping review and evidence map was registered in the Open Science Framework (OSF) Registries (osf.io/my7pb) (21) and performed according to The Center for Open Science's Transparency and Openness Promotion Guidelines (22). Scoping reviews and evidence maps were not eligible for registration in the international prospective register of systematic reviews at the initiation of this work (i.e., PROSPERO). A systematic review and quantitative meta-analysis were not included as part of this review.

Systematic Search

Literature searches were conducted in PubMed, Cochrane Library, and Scopus on 24 August 2021. There were no restrictions on the publication period. Research presented in languages other than English was excluded. Search strings were developed and tested to ensure the collection of relevant studies. The search strings used to conduct the search

Funded by the USDA Agricultural Research Service (ARS) Beltsville Human Nutrition Research Center (BHNRC) Food Components and Health Laboratory (FCHL) with supplemental funding from the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) Low- and No-Calorie Sweeteners Committee and the IAFNS Carbohydrates Committee. IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. IAFNS had no such involvement or restrictions regarding publication.
Author disclosures: KAH was previously an employee at Exponent Inc. from January 2019 to April 2021. DJB is a Federal liaison to the IAFNS Carbohydrate and Lipid committees. KMA has received funding for research from Unilever R&D Vlaardingen, NL, and ILSI–North America for research on sweet taste; has current funding from TIFN, NL (in collaboration with Arla Foods, DK, American Beverage Association, US, Cargill, US, Dutch Knowledge Centre for Sugar, NL, Firmenich, CH, International Sweeteners Association, BE, SinoSweet, China, Unilever, and NL); and from the International Sweeteners Association; and has received speaker's expenses from the International Sweeteners Association, PepsiCo, and ILSI-North America. All other authors report no conflicts of interest.
Supplemental Methods and Supplemental References are available from the "Supplementary data" link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/advances/.
Address correspondence to KAH (email: Kelly.Higgins@usda.gov).
Abbreviations used: BW, body weight; EI, energy intake; IAFNS, Institute for the Advancement of Food and Nutrition Sciences; LCS, low-calorie sweetener(s); OSF, Open Science Framework; PI(E)COS, Populations, Interventions/Exposures, Comparators, Outcomes, and Study Designs or Settings; RCT, randomized controlled trial; SSB(s), sugar-sweetened beverage(s); VAS, visual analog scale; W:H, waist to hip; WC, waist circumference

are provided in **Supplemental Methods**. Results from the database searches were managed using EndNote X9.

Eligibility Criteria

The Population, Intervention/Exposure, Comparator, Outcome, and Study Design or Setting [PI(E)COS] criteria for inclusion in this review are included in **Table 1**.

Population.

Studies conducted among adults (age ≥18 y) were considered suitable for inclusion. Studies conducted among child/adolescent populations (age <18 y) that tracked measures of BW into adulthood (age ≥18 y) were included, but studies that focus solely on BW outcomes in childhood were not considered. The primary populations of interest were generally healthy individuals; however, studies conducted among populations with diseases prevalent in Western populations (e.g., obesity, hypertension, hyperlipidemia, type II diabetes) were also considered. Populations with chronic diseases (e.g., cancer, chronic kidney disease, chronic lung disease, heart disease, HIV/AIDS), metabolic disorders (e.g., irritable bowel syndrome, phenylketonuria, maple syrup urine disease), or clinical nutrient deficiencies were excluded. Studies among populations who had sensory disorders or eating disorders, had undergone bariatric surgery, or were taking appetite suppressants or other antiobesity medications or supplements (23–26) were also not considered for study inclusion. Studies among pregnant and lactating populations were excluded.

Interventions.

The primary interventions/exposures of interest in this review were studies that investigated total dietary sweetness. However, due to the challenges associated with defining the sweetness of the diet, studies that investigated the frequency and/or quantity of foods/beverages that were described as sweet or sweetened or were conventionally considered to be sweet [i.e., food/beverages with high sweetness ratings in taste databases (27–29)] were also considered as supportive evidence. Examples of foods/beverages that were conventionally considered sweet include, but are not limited to, sugar sweetened beverages (SSBs), LCS beverages, cakes, pies, cookies, ice cream, pastries, candy, sweetened dairy products, chewing gums, fruit, and fruit juices. Studies on diets high in total sugars, added sugars, or LCSs were also considered for inclusion, but studies on food sources that may be high in mono- or disaccharides or LCS that are not designated as sweet were excluded (e.g., sandwich bread, condiments). In addition, studies that provide sweeteners without oral exposure (e.g., encapsulated, intravenous) were not considered. Studies that investigated the effects of dietary patterns high or low in sugar and/or sweet foods/beverages that did not provide sufficient information to differentiate the level of sweetness between treatment and control interventions/exposures and included other components of the dietary pattern that may influence BW-related outcomes were excluded [e.g., Western compared with Mediterranean dietary pattern, Western compared with DASH dietary pattern, high compared with low glycemic dietary pattern].

Comparison.

To be included in the evidence map, all studies were required to include a low sweet comparator. Studies that compared results between treatments with the same level of sweetness were excluded. Studies that did not have a comparator group and provided comparisons to baseline only were excluded due to the inability to control for confounding factors that may have occurred throughout the study.

Outcomes.

Primary outcomes of interest were BW and BMI (kg/m^2). Secondary outcomes were measures of EI and adiposity. Potential measures of adiposity included but were not limited to fat mass, body fat percentage, waist circumference (WC), and waist-to-hip ratio (W:H ratio). Studies that only included measurement of EI or a BW-related outcome as part of safety monitoring, compliance, or measures of hydration status were excluded. Studies that reported food/beverage intakes in weight or volume that could not be converted to EI were excluded.

Study Design.

This evidence map included clinical trials, longitudinal cohorts, case–control studies, and cross-sectional studies published in peer-reviewed journals. Results from studies published as conference abstracts were excluded.

Screening and Selection

Screening of the search results was managed using Microsoft Access. Screening templates were developed and piloted prior to the literature search. Additional duplicates beyond those identified in EndNote were identified, based on title, author, and journal information, and removed. Automated tools (summarized in Supplemental Methods) were developed to screen out studies based on the specified inclusion/exclusion criteria. For the remaining publications, 2 reviewers (KAH, RR) independently determined if a publication met the inclusion/exclusion criteria based on the title and abstract. Publications that both reviewers determined to be ineligible were excluded. During the second round of screening, 2 reviewers (KAH, RR) determined if the screened publications met the inclusion/exclusion criteria based on the entire research article with discrepancies resolved by a third reviewer if necessary (DJB or KMA). A PRISMA flow diagram was completed to outline the identification of relevant studies included in this review.

Data Extraction

Publications that reported results from multiple studies were disaggregated and classified as separate studies, and multiple publications from the same study were aggregated in order to determine the number of relevant studies (as opposed to the number of publications). These included studies that provided 2 different types of analyses (e.g., data from a

TABLE 1 PI(E)COS criteria to identify studies that investigated the association between dietary sweetness and BW-related outcomes and/or EI among adults[1]

Inclusion criteria	Exclusion criteria
Population	
Adults (≥18 y)	Children/adolescent populations that do not track BW into adulthood
Generally healthy or with disease prevalent among Western populations[2]	Populations with eating disorders or sensory disorders
Children/adolescent populations that track BW into adulthood	Bariatric surgery patients
	Populations taking medications known to affect sensory perception, appetite, or BW[3]
	Populations with chronic diseases,[4] metabolic disorders,[5] or clinical nutrient deficiencies
	Pregnant or breastfeeding populations
Intervention/exposures	
Primary: high total dietary sweetness	Sweeteners delivered without oral exposure[6]
Secondary: more frequent or higher intake of sweet food/beverage consumption	Foods or dietary pattern high in sugars, LCS, or SSB that are not considered sweet[7]
Tertiary: higher intake of total/added sugars or sweeteners	
Comparison	
Primary: low total dietary sweetness	Comparisons to control with the same level of sweetness[8]
Secondary: less frequent or lower intake of sweet food/beverage consumption	Comparison to baseline only (i.e., no control group)
Tertiary: lower intake of total/added sugars or sweeteners	Foods or dietary pattern low in sugars, LCS, or SSB that are not considered low sweet[9]
Outcomes	
Primary: BW, BMI	BW-related outcome for safety monitoring, compliance, or hydration
Secondary: EI, fat mass, body fat %, WC, W:H ratio	Food/beverage intake reported in weight or volume that cannot be converted to EI
Study design/setting	
Clinical trials, observational studies (i.e., cross-sectional, longitudinal cohort, case control), systematic reviews, meta-analyses	Case studies, animal trials, in vitro trials, narrative reviews, opinion articles, position papers, protocols (i.e., no results reported), ecological analysis, descriptive analysis, conference abstracts

[1] BW, body weight; EI, energy intake; LCS, low-calorie sweetener(s); PI(E)COS, populations, interventions/exposures, comparators, outcomes, and study designs or settings; SSB, sugar-sweetened beverage(s); WC, waist circumference; W:H, waist to hip.
[2] Includes obesity, hypertension, hyperlipidemia, type II diabetes.
[3] Includes acetazolamide, amiodarone, benzphetamine, captopril, cisplatin, diethylpropion, ephedrine, eszopiclone, liraglutide, lithium, lorcaserin, maribavir, naltrexone-bupropion, orlistat, phendimetrazine, phentermine, phenylpropanolamine, procainamide, terbinafine, topiramate (23–26).
[4] Includes cancer, chronic kidney disease, chronic lung disease, heart disease, HIV/AIDS.
[5] Includes irritable bowel syndrome, phenylketonuria, maple syrup urine disease.
[6] Includes intravenous and encapsulated.
[7] Includes savory sauces or dishes
[8] Interventions/exposures with the same level of sweetness. If a study compared 2 sugars (e.g., glucose compared with fructose, sucrose compared with high-fructose corn syrup) but did not provide information on the sweetness intensity, the comparisons were considered to be the same sweetness and excluded.
[9] Includes Mediterranean dietary pattern, Dietary Approaches to Stop Hypertension (DASH) dietary pattern, low glycemic dietary pattern

RCT reported in 2 publications, data from a baseline and follow-up from the same longitudinal cohort). Studies were classified under the study design type of strongest quality of evidence (30) or relevance of the intervention/exposure and outcomes. Key study characteristics were extracted from eligible studies that investigated the effects of total dietary sweetness, sweet foods/beverages, sugars, and sweeteners on BW-related outcomes by 2 reviewers (KAH, RR, DJB, LEO, or KMA). Relevant characteristics included study design, description of sweetness intervention/exposure, description of comparator intervention/exposure, methods to evaluate sweetness, population characteristics (age, gender, BW status, health status), sample size, study duration, and outcomes measured. Within the descriptions of the sweetness intervention/exposure and comparator, information on delivery vehicle (e.g., solid, liquid, total diet) and relative differences in energy content between the intervention/exposure and comparator were extracted. Information on how specific characteristics were extracted from the studies is provided in Supplemental Methods.

A list of relevant systematic reviews and meta-analyses identified in the literature search was tabulated. These publications were not analyzed further in the current evidence map, because each of these systematic reviews addressed relevant but different research questions, including different population, intervention/exposure, and comparator.

Hierarchy of Evidence

A hierarchy of evidence was created to classify relevant studies that investigated the association between sweetness interventions/exposures and BW-related outcomes based on the sweetness interventions/exposures depicted in **Figure 1**: total dietary sweetness, sweet foods/beverages, sugar, sweetener, or other sweet intake. Within each of these levels, a further distinction was made between the studies that measured the sweet taste of the diets, foods, and beverages



FIGURE 1 Categories and definitions of dietary sweetness exposures included in the scoping review and evidence map.

using a sensory method (i.e., sweetness measured) and those where the sweet taste was assumed based on the contents of the intervention/exposure (i.e., sweetness assumed).

Of primary importance were the studies that evaluated the sweetness of the entire diet (i.e., total dietary sweetness), because no/minimal assumptions were needed to classify the level of sweetness of the intervention/exposure and comparator diets. Secondary importance was given to studies that investigated diets high in specific sweet foods/beverages [i.e., foods/beverages described as sweet or conventionally considered sweet (27–29)], sugars [i.e., added and/or total sugars (31, 32)], or sweeteners (i.e., LCSs or other energetic or nonenergetic sweeteners used as substitutes or alternatives for sugar), because only 1 or limited elements of the diet that contribute sweetness were evaluated in these studies (i.e., individual sweet foods/beverages, sugars, or sweeteners) as opposed to sweetness from all dietary sources (i.e., total dietary sweetness). Interventions/exposures that were sweet but high in dietary bioactives (e.g., fruits, 100% fruit juices, sweetened dairy products), sweet oral exposures that were not swallowed (e.g., chewing gum, oral rinses), or additives that alter sweet taste perception (e.g., sweetness enhancers, sweetness antagonists) that could influence the outcomes of interest were classified as "other" sweet interventions/exposures.

In addition to the sweet interventions/exposures classified above, additional studies that investigated the association between sweet dietary patterns and BW were identified in the search. A dietary pattern study incorporated multiple components of the diet to describe an individual's eating behavior. A sweet dietary pattern was either described as sweet by the authors or included sweet food/beverage components within the dietary pattern. These studies were included in the evidence map but considered separately and not further analyzed, because a low sweet comparator of direct comparability to the intervention could not be confirmed in these studies.

Data Synthesis

Summary data on study counts were compiled in a tabular and graphical form and accompanied by a descriptive summary. The number of studies and population characteristics were summarized by sweetness intervention/exposure type (total dietary sweetness, sweet foods/beverages, sugar, sweetener, or other sweet intake) for all included studies. Studies that evaluated multiple sweet dietary interventions/exposures (e.g., sugar and LCS intake, SSB, and fruit juice intake) were included in multiple levels within the hierarchy of evidence. Population characteristics of the study included age, sex, health status, and BW status. Studies were further categorized as a clinical trial, longitudinal cohort, case–control study, cross-sectional study, or other study design (e.g., study design not specified, secondary or post-hoc analyses of a RCT in which the randomized intervention was not an eligible sweetness intervention/exposure). Information on sample size, study duration, and outcomes measured was tabulated for each sweetness intervention/exposure and study design. Heat maps were developed to graphically depict



FIGURE 2 PRISMA flow diagram of studies that investigated the association between dietary sweetness and body weight-related outcomes among adults included in the scoping review and evidence map. [1]Duplicates removed not captured by EndNote. [2]Automation tools described in Supplemental Methods.

the number of studies by sweetness intervention/exposure, study design, and outcomes reported. All tables and heat maps were completed using Microsoft Excel and SAS software, Version 9.4.

Results

The study flow of this evidence map is outlined in **Figure 2**. A total of 36,779 publications (duplicates removed with EndNote) were recovered in the literature searches. Of these, 33,569 publications were excluded during the title and abstract screening. An additional 2,377 publications were excluded during the full text review. Therefore, 833 publications summarizing results from 804 studies were determined to meet the inclusion criteria. These studies included 227 clinical trials (28.2% of all included studies), 81 longitudinal cohorts (10.1%), 4 case–control studies (0.5%), 284 cross-sectional studies (35.3%), and 19 studies of other design (2.4%) that investigated the association between total dietary sweetness, sweet foods/beverages, sugar, sweetener, or other sweet exposure intake and a BW-related outcome and/or EI (references included in **Supplemental References**). Ninety-two studies (11.4%) that investigated the association between a sweet dietary pattern and a BW-related outcome and/or EI were identified in the literature search. In addition, 97 systematic reviews (12.1%) that addressed relevant but different research questions related to sweetness interventions/exposures and BW and/or EI were identified. A list of these studies is provided in Supplemental References.

Summary characteristics by sweetness intervention/exposure type are described below and presented in both the graphical and tabular format. Each category of sweetness intervention/exposure is described by study design, duration,

method used to evaluate sweetness, and outcomes reported. Summary population characteristics are provided in **Table 2**. Study duration and sample size by type of sweetness intervention/exposure are summarized in **Tables 3** and **4**, respectively. Heat maps of the number of studies identified by sweetness intervention/exposure and study design type for each outcome (BW/BMI, EI, fat mass/body fat percentage, and WC/W:H ratio) are displayed in **Figure 3**. Characteristics of each of the individual studies are included in the accompanying Microsoft Access database (osf.io/ckh9v/) (33).

Studies on total dietary sweetness intake

Study Design.

A total of 7 studies (0.9% of all included studies) investigated associations between total dietary sweetness and a BW-related outcome and/or EI. These studies were 2 clinical trials (34, 35), 4 cross-sectional studies (36–39), and 1 other study design (40).

Duration.

One of the clinical trials controlled the sweetness of the diet for 24 h (34) and 1 controlled sweetness for 24 wk with an additional 24 wk follow-up after the sweetness intervention was completed (35). The cross-sectional studies were based on either two 24 h dietary recalls (36, 37, 39) or 4 weighed dietary records (38). One study of other design type used crowd-sourced MyFitnessPal data from an unspecified duration to evaluate the correlation between taste exposures and BMI (40).

Methods to evaluate sweetness.

Although the 2 clinical trials compared diets that were designed to be of different levels of sweetness, neither trial directly quantified the sweetness of the whole diet. Three of the 4 cross-sectional studies used taste databases to estimate the sensory profile of foods consumed within the diet. These databases were developed using modified versions of the Spectrum ^{TM} method (41) of quantitative descriptive analysis to measure the sensory profile of 476 (36, 37) or >720 (39) foods commonly consumed foods/beverages. The other cross-sectional study had participants assign a predominant taste to each food consumed in a series of 4 food records to estimate total dietary sweetness exposure (38). The crowd-sourced study used a machine learning algorithm to classify foods by taste from crowd sourced data, but did not measure the sweetness of the foods consumed (40).

Outcomes.

BW, BMI, EI, and WC were measured in the clinical trial that exposed individuals to isoenergetic high and low sweetness diets for 24 wk (35). No difference in BW or BMI were observed after 24 wk of sweetness intervention and both diets achieved a similar reduction in EI, yet a larger decrease in WC was observed among participants consuming the low sweetness diet compared with the high sweetness diet. EI was measured in the clinical trial ≤24 h in duration (34); no difference in ad libitum EI was observed between a predominantly sweet compared with predominantly savory or mixed diet. BW and EI were measured in 3 of the 4 cross-sectional studies, whereas 1 study only measured EI (38). The only relevant outcome reported in the crowd-sourced study was BMI (40). Among these studies, individuals with obesity consumed less energy from sweet tasting foods compared with normal weight individuals [men (37); (40)] or consumed levels of sweet tasting foods/beverages that were not significantly different than normal weight individuals [women (37); (38, 39)]; no difference in percent of energy from sweet tasting foods was identified between individuals with normal weight were compared with individuals with overweight or obesity (36).

Studies on sweet food/beverage intake

Study Design.

A total of 433 studies (53.9% of all included studies) investigated the associations between intake of sweet foods/beverages and a BW-related outcome and/or EI. These studies included 135 clinical trials, 67 longitudinal cohorts, 3 case–control studies, 212 cross-sectional studies, and 16 studies of other study design. Within the clinical trials, 46 clinical trials (5.7% of all included studies) measured the sweetness of the foods/beverage exposures; no longitudinal cohorts, case–control studies, cross-sectional studies, or studies of other study design measured the sweetness of the exposures.

The studies within this level of evidence assessed exposure to 1 or more sweet foods/beverages. Among the studies that measured the sweetness of the exposure (n = 46), the exposures included intakes of SSB (n = 22 studies), sugar sweetened solid/semi-solid foods (n = 19), LCS beverages (n = 17), and LCS solid/semi-solid foods (n = 8). Note that the sum of these exposures does not add to 46 studies, because some studies provided multiple exposures (e.g., a SSB arm and a LCS beverage arm). In studies that did not measure sweetness (n = 387), sweetness exposures included intakes of SSB (n = 279), sugar sweetened solid/semi-solid foods (n = 149), LCS beverages (n = 115), and LCS solid/semi-solid foods (n = 5).

Duration.

The clinical trials that measured the sweetness of the exposure were generally short in duration, with 40 of the 46 studies lasting ≤24 h in duration. The remaining 6 studies were >24 h to <4 wk in duration. Of the studies in which the sweetness of the exposure was assumed based on the foods/beverages consumed (n = 89 studies), the clinical trials ranged from ≤24 h to <5 y in duration, with most of the studies (n = 53) lasting ≤24 h. The longitudinal cohort studies (n = 67) ranged from 4 wk to ≥ 10 y in duration, with the majority of cohorts (n = 39) lasting ≥5 y.

TABLE 2 Summary population characteristics of studies that investigated the association between dietary sweetness and BW-related outcomes among adults by sweetness exposure (615 studies)[1]

	Sweetness intervention/exposure[2]					
	Total dietary sweetness ($n = 7$)	**Sweet food/bev, measured[3] ($n = 46$)**	**Sweet food/bev, assumed[4] ($n = 387$)**	**Sugars[5] ($n = 129$)**	**Sweeteners[5] ($n = 32$)**	**Other[6] ($n = 127$)**
Population characteristics[7]						
Age, y						
<18	0 (0)	0 (0)	11 (1.8)	3 (0.5)	0 (0)	1 (0.2)
18–64	2 (0.3)	41 (6.7)	200 (32.5)	56 (9.1)	16 (2.6)	71 (11.5)
≥65	0 (0)	0 (0)	0 (0)	3 (0.5)	0 (0)	0 (0)
<18–64	0 (0)	0 (0)	8 (1.3)	4 (0.7)	0 (0)	2 (0.3)
18 to ≥65+	5 (0.8)	1 (0.2)	145 (23.6)	55 (8.9)	13 (2.1)	45 (7.3)
<18 to ≥ 65+	0 (0)	0 (0)	14 (2.3)	6 (1.0)	2 (0.3)	4 (0.7)
Age not specified	0 (0)	4 (0.7)	9 (1.5)	2 (0.3)	1 (0.2)	4 (0.7)
BW status[8]						
All BMIs	2 (0.3)	0 (0)	165 (26.8)	45 (7.3)	15 (2.4)	50 (8.1)
Normal weight–obese	2 (0.3)	1 (0.2)	46 (7.5)	11 (1.8)	5 (0.8)	19 (3.1)
Normal weight–overweight	0 (0)	14 (2.3)	27 (4.4)	17 (2.8)	2 (0.3)	5 (0.8)
Normal weight	1 (0.2)	20 (3.3)	39 (6.3)	8 (1.3)	5 (0.8)	23 (3.7)
Overweight	0 (0)	2 (0.3)	21 (3.4)	10 (1.6)	0 (0)	3 (0.5)
Overweight–obese	1 (0.2)	0 (0)	29 (4.7)	10 (1.6)	0 (0)	5 (0.8)
Obese	0 (0)	0 (0)	14 (2.3)	4 (0.7)	3 (0.5)	6 (1.0)
Other[9]	1 (0.2)	5 (0.8)	16 (2.6)	7 (1.1)	1 (0.2)	9 (1.5)
Not specified	0 (0)	4 (0.7)	30 (4.9)	17 (2.8)	1 (0.2)	7 (1.1)
Gender						
Females	0 (0)	10 (1.6)	56 (9.1)	15 (2.4)	2 (0.3)	23 (3.7)
Males	0 (0)	12 (2.0)	32 (5.2)	14 (2.3)	1 (0.2)	15 (2.4)
Males/females	7 (1.1)	24 (3.9)	294 (47.8)	97 (15.8)	29 (4.7)	88 (14.3)
Not specified	0 (0)	0 (0)	5 (0.8)	3 (0.5)	0 (0)	1 (0.2)
Health status[10,11]						
Generally healthy[12]	7 (1.1)	46 (7.5)	376 (61.1)	106 (17.2)	27 (4.4)	125 (20.3)
	0 (0)	0 (0)	7 (1.1)	18 (2.9)	4 (0.7)	1 (0.2)
Prediabetes/diabetes						
Prehypertensive/hypertensive	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	0 (0)
Hyperlipidemia	0 (0)	0 (0)	0 (0)	2 (0.3)	0 (0)	1 (0.2)
Other[13]	0 (0)	0 (0)	3 (0.5)	4 (0.7)	1 (0.2)	0 (0)

[1]Values are presented as *n* (%) of 615 included studies. Percentages within a characteristic may not sum to 100%, because some studies investigated multiple sweetness exposures (e.g., 1 study that investigated both sugars and sweeteners). bev, beverages; BW, body weight.
[2]See Figure 1 and "Hierarchy of Evidence" for definitions of each sweetness exposure type. The sum of all sweetness intervention/exposure categories does not sum to the total number of studies identified ($n = 804$), because some studies analyzed multiple sweetness interventions/exposures.
[3]Sweet foods/beverages, sweetness of foods/beverages measured.
[4]Sweet foods/beverages, sweetness of foods/beverages assumed.
[5]None of the studies that investigated these exposures measured the sweetness of the intervention/exposure; therefore, sweetness was assumed.
[6]Includes studies where the sweetness of the intervention/exposure was measured or assumed.
[7]Information on how this population characteristic data was extracted from the included studies is summarized in Supplemental Methods.
[8]BW status of population included in relevant analyses. This information was based on the inclusion criteria, if provided, or the summary population characteristics; population characteristics at baseline were used for clinical trials and longitudinal studies. If the inclusion criteria were not provided, then the BMI was based on range, prevalence of BMI categories, mean/median BMI of the population, or BW status as described by the study's authors. If prevalence of BMI categories (e.g., 25% of sample was overweight or obese) did not add up to 100%, then it was assumed that all BMI categories were represented in the sample.
[9]Other BW statuses including normal weight and obese; underweight, normal weight, and overweight; and underweight and normal weight.
[10]Population or subgroup of the population reported to have a disease prevalent among Western populations (i.e., hypertension, hyperlipidemia, type II diabetes) as defined by the study author. This diagnosis was not based on biomarkers that may be reported in the manuscript.
[11]Not all study counts add to the sum of the number of studies per sweetness intervention/exposure for this characteristic. This is because some studies include multiple categories (e.g., 1 study that investigated sugar intake included individuals with both diabetes and hyperlipidemia).
[12]Generally healthy as stated by study authors or the health status of the population was not explicitly stated to be diseased.
[13]Population or subgroup of the population reported to have another disease state that was not considered to be an excluded population (e.g., nonalcoholic fatty liver disease, morbid obesity, kidney transplant patients, arthritis).

TABLE 3 Study duration of clinical trials and longitudinal cohort studies that investigated the association between dietary sweetness and BW-related outcomes among adults by sweetness exposure (227 clinical trials and 81 longitudinal cohorts)[1]

	Sweetness exposure[2]					
	Total dietary sweetness	Sweet food/bev, measured[3]	Sweet food/bev, assumed[4]	Sugars[5]	Sweeteners[5]	Other[6]
Clinical trials	$n = 2$	$n = 46$	$n = 89$	$n = 44$	$n = 9$	$n = 49$
≤24 h	1 (0.4)	40 (17.6)	53 (23.3)	0 (0)	4 (1.8)	36 (15.9)
>24 h to <4 wk	0 (0)	6 (2.6)	11 (4.8)	12 (5.3)	0 (0)	3 (1.3)
4 wk to <0.5 y	1 (0.4)	0 (0)	11 (4.8)	28 (12.3)	4 (1.8)	10 (4.4)
0.5 to <1 y	0 (0)	0 (0)	9 (4.0)	4 (1.8)	1 (0.4)	0 (0)
1 to <5 y	0 (0)	0 (0)	5 (2.2)	0 (0)	0 (0)	0 (0)
Longitudinal cohort	$n = 0$	$n = 0$	$n = 67$	$n = 15$	$n = 4$	$n = 22$
4 wk to <0.5 y			3 (3.7)	0 (0)	0 (0)	0 (0)
0.5 to <1 y			4 (4.9)	0 (0)	0 (0)	3 (3.7)
1 to <5 y			21 (25.9)	5 (6.2)	3 (3.7)	8 (9.9)
5 to <10 y			19 (23.5)	5 (6.2)	0 (0)	5 (6.2)
10 y			20 (24.7)	5 (6.2)	1 (1.2)	6 (7.4)

[1]Values are presented as *n* (%) of 227 clinical trials and 81 longitudinal cohorts. Percentages within a characteristic may not sum to 100%, because some studies investigated multiple sweetness exposures (e.g., 1 study that investigated both sugars and sweeteners). bev, beverages; BW, body weight.
[2]See Figure 1 and "Hierarchy of Evidence" for definitions of each sweetness exposure type. The sum of all of the sweetness intervention/exposure categories does not sum to the total number of studies identified ($n = 804$), because some studies analyzed multiple sweetness interventions/exposures.
[3]Sweet foods/beverages, sweetness of foods/beverages measured.
[4]Sweet foods/beverages, sweetness of foods/beverages assumed.
[5]None of the studies that investigated these exposures measured the sweetness of the intervention/exposure; therefore, sweetness was assumed.
[6]Includes studies where the sweetness of the intervention/exposure was measured or assumed.

Methods to evaluate sweetness.

Among the studies that measured sweetness of the foods/beverage exposures ($n = 46$), the most common method used to measure sweetness was a visual analog scale (VAS) ($n = 27$, 58.7% of studies that measured sweetness). Other methods included categorical scales ($n = 3$, 6.5%), sweet taste recognition ($n = 2$, 4.3%), labeled magnitude scale ($n = 1$, 2.2%), magnitude estimation ($n = 1$, 2.2%), discrimination ($n = 1$, 2.2%), or did not specify the method used ($n = 12$, 26.1%). Note, 1 study used 2 measurement methods to evaluate sweetness (42), thus numbers of studies do not total 46.

Outcomes.

Due to the short duration of the clinical trials that measured sweetness, EI was the predominant outcome of interest measured in all 46 studies. BW and/or BMI was measured in 2 of the 46 studies (4.3%). This observation is consistent with the studies that assumed sweetness of the exposure. EI was the most common outcome measured in the clinical trials both ≤ and >24 h in duration. There were 27 that measured BW in the 36 clinical trials >24 h in duration. Other outcomes measured in clinical trials >24 h in duration included fat mass and/or body fat percentage ($n = 8$, 22.2%) and WC and/or W:H ratio ($n = 13$, 36.1%). Among the 67 longitudinal cohorts, 63 studies (94.0%) measured BW and/or BMI, 20 studies (29.9%) measured EI, 5 studies (7.5%) measured fat mass and/or body fat percentage, and 20 studies (29.9%) measured WC and/or W:H ratio. Among the 3 case–control studies, BW and/or BMI was reported in 3 studies, EI was reported in 1 study, and WC and/or W:H ratio was reported in 1 study. Among the 212 cross-sectional studies, 194 studies (91.5%) reported BW and/or BMI, 62 studies (29.2%) reported EI, 13 (6.1%) studies reported fat mass and/or body fat percentage, and 48 (22.6%) studies reported WC and/or W:H ratio. Among the 16 studies of other design type, all 16 studies (100%) reported BW and/or BMI, 5 studies (31.3%) reported EI, 2 studies (12.5%) reported fat mass and/or body fat percentage, and 4 studies (25.0%) reported WC and/or W:H ratio.

For some of the studies ($n = 30$, 6.9% of the 433 studies) that investigated intake of sweet foods/beverages (both measured and assumed sweetness), the sweetness exposure was also the outcome measurement (e.g., amount of sweet food consumed from a choice of sweet and nonsweet foods, ad libitum intake of sweet food). This measure of EI (measurement of ad libitum energy from sweet foods/beverages) is different from studies that investigate EI of subsequent meals after sweet food/beverage intake. These studies were included because they met the inclusion/exclusion criteria of this evidence map. However, the search terms were not designed to capture all studies that measured sweet food intake as an outcome; therefore, this may not be a comprehensive list of studies.

Studies on sugar intake

Study Design.

A total of 129 studies (16.0% of all studies included) investigated the associations between sugar intake and a BW-related outcome and/or EI. These studies were 44 clinical trials, 15 longitudinal cohorts, 68 cross-sectional studies, and 2 of other study design.



FIGURE 3 Heat maps of specific outcomes reported in studies that investigated the association between dietary sweetness and body weight-related outcomes among adults by study design type and sweetness exposure. Number of studies that measured BW and/or BMI (A). B, Number of studies that measured energy intake (B). Number of studies that measured fat mass and/or body fat percentage (C). Number of studies that measured WC and/or W:H ratio (D). The different colors represent the different numbers of studies that reported each outcome by study design type and sweetness exposure.

Duration.

The 44 clinical trials investigating the association between sugar intake and BW-related outcomes and/or EI were all >24 h in duration, with most studies ($n = 28$) investigating sugar intake for 4 wk to < 0.5 y. The 15 cohort studies were all at least a year in duration: either 1 to <5 y ($n = 5$), 5 to <10 y ($n = 5$), or ≥10 y ($n = 5$) in duration. One study of other design type [a secondary analysis of a weight loss RCT with follow-up (43)], lasted 1 to <5 y; another study of other design type was a pre-post intervention, but the only relevant analyses for this scoping review and evidence map were cross-sectional in nature (44). The remaining studies were all cross-sectional analyses.

Methods to evaluate sweetness.

None of these studies measured the sweetness of the intervention/exposure.

Outcomes.

BW and/or BMI were the most common outcomes measured across all study design types [measured in $n = 41$ (93.2%) clinical trials, $n = 15$ (100%) longitudinal cohorts, $n = 62$ (91.2%) cross-sectional, $n = 2$ (100%) other study designs], followed by EI [$n = 28$ (63.6%), $n = 7$ (46.7%), $n = 32$ (47.1%), $n = 0$ (0%), respectively], WC and/or W:H ratio [$n = 11$ (25.0%), $n = 6$ (40.0%), $n = 26$ (38.2%), $n = 0$ (0%), respectively], and fat mass and/or body fat percentage [$n = 15$ (34.1%), $n = 2$ (13.3%), $n = 4$ (5.9%), $n = 0$ (0%), respectively].

Studies on sweetener intake

Study Design.

A total of 32 studies (4.0% of all included studies) investigated the associations between sweetener intake and a BW-related outcome and/or EI. These studies were 9 clinical trials, 4 longitudinal cohorts, 1 case–control study, and 18 cross-sectional studies.

Duration.

The clinical studies were either ≤24 h ($n = 4$ studies), 4 wk to <0.5 y ($n = 4$), or 0.5 to <1y ($n = 1$) in duration. The longitudinal cohorts were either 1 to <5 y ($n = 3$) or ≥10 y ($n = 1$) in duration.

Methods to evaluate sweetness.

One RCT measured the sweetness of sucralose, sucralose and maltodextrin, and water solutions using a VAS (45). The remaining 31 studies did not measure the sweetness of the intervention/exposure.

TABLE 4 Sample size of studies that investigated the association between dietary sweetness and BW-related outcomes among adults by sweetness exposure and study design type (615 studies)[1]

	Sweetness intervention/exposure[2]					
	Total dietary sweetness	Sweet food/bev, measured[3]	Sweet food/bev, assumed[4]	Sugars[5]	Sweeteners[5]	Other[6]
Clinical trials	*n* = 2	*n* = 46	*n* = 89	*n* = 44	*n* = 9	*n* = 49
≤10	0 (0)	4 (1.8)	7 (3.1)	6 (2.6)	1 (0.4)	6 (2.6)
11–20	0 (0)	16 (7.0)	17 (7.5)	13 (5.7)	3 (1.3)	9 (4.0)
21–50	1 (0.4)	21 (9.3)	30 (13.2)	12 (5.3)	1 (0.4)	16 (7.0)
51–100	0 (0)	5 (2.2)	17 (7.5)	10 (4.4)	2 (0.9)	12 (5.3)
101–500	1 (0.4)	0 (0)	17 (7.5)	3 (1.3)	2 (0.9)	6 (2.6)
501–1000	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)
Longitudinal cohort	*n* = 0	*n* = 0	*n* = 67	*n* = 15	*n* = 4	*n* = 22
51–100			2 (2.5)	0 (0)	0 (0)	1 (1.2)
101–500			13 (15)	1 (1.2)	2 (2.5)	3 (3.7)
501–1000			5 (6.2)	0 (0)	0 (0)	0 (0)
1001–5000			18 (22.2)	12 (14.8)	1 (1.2)	4 (4.9)
5001–10,000			10 (12.3)	0 (0)	0 (0)	3 (3.7)
10,001–20,000			5 (6.2)	1 (1.2)	0 (0)	3 (3.7)
≥20,001			14 (17.3)	1 (1.2)	1 (1.2)	8 (9.9)
Case–control	*n* = 0	*n* = 0	*n* = 3	*n* = 0	*n* = 1	*n* = 0
51–100			0 (0)		1 (25.0)	
101–500			2 (50.0)		0 (0)	
501–1000			0 (0)		0 (0)	
1001–5000			0 (0)		0 (0)	
5001–10,000			0 (0)		0 (0)	
10,001–20,000			0 (0)		0 (0)	
≥20,001			1 (25.0)		0 (0)	
Cross-sectional	*n* = 4	*n* = 0	*n* = 212	*n* = 68	*n* = 18	*n* = 50
21–50	0 (0)		4 (1.4)	1 (0.4)	0 (0)	1 (0.4)
51–100	1 (0.4)		6 (2.1)	3 (1.1)	1 (0.4)	1 (0.4)
101–500	0 (0)		57 (20.1)	20 (7.0)	6 (2.1)	15 (5.3)
501–1000	1 (0.4)		25 (8.8)	5 (1.8)	1 (0.4)	4 (1.4)
1001–5000	1 (0.4)		55 (19.4)	24 (8.5)	5 (1.8)	15 (5.3)
5001–10,000	1 (0.4)		22 (7.7)	5 (1.8)	0 (0)	3 (1.1)
10,001–20,000	0 (0)		11 (3.9)	6 (2.1)	3 (1.1)	4 (1.4)
≥20,001	0 (0)		31 (10.9)	4 (1.4)	2 (0.7)	7 (2.5)
Not specified	0 (0)		1 (0.4)	0 (0)	0 (0)	0 (0)
Other study design[7]	*n* = 1	*n* = 0	*n* = 16	*n* = 2	*n* = 0	*n* = 6
21–50	0 (0)		0 (0)	2 (10.5)		1 (5.3)
51–100	0 (0)		3 (15.8)	0 (0)		1 (5.3)
101–500	0 (0)		7 (36.8)	0 (0)		1 (5.3)
501–1000	0 (0)		1 (5.3)	0 (0)		0 (0)
1001–5000	0 (0)		3 (15.8)	0 (0)		2 (10.5)
5001–10,000	0 (0)		0 (0)	0 (0)		0 (0)
10,001–20,000	0 (0)		1 (5.3)	0 (0)		1 (5.3)
≥20,001	1 (5.3)		1 (5.3)	0 (0)		0 (0)

[1]Values are presented as *n* (%) of 227 clinical trials, 81 longitudinal cohorts, 4 case–control studies, 284 cross-sectional studies, and 19 studies of other study design types, respectively. Percentages within a study design type may not sum to 100%, because some studies investigated multiple sweetness exposures (e.g., 1 study that investigated both sugars and sweeteners).
[2]See Figure 1 and "Hierarchy of Evidence" for definitions of each sweetness exposure type. The sum of all of the sweetness exposure categories does not add to the total number of studies identified, because some studies analyzed multiple sweetness interventions/exposures.
[3]Sweet foods/beverages, sweetness of foods/beverages measured.
[4]Sweet foods/beverages, sweetness of foods/beverages assumed.
[5]None of the studies that investigated these exposures measured the sweetness of the intervention/exposure; therefore, sweetness was assumed.
[6]Includes studies where the sweetness of the intervention/exposure was measured or assumed.
[7]Includes study design not specified, secondary analyses of RCT in which the primary intervention was not an included sweetness exposure.

Outcomes.

BW and/or BMI were measured in all clinical trials >24 h in duration; clinical trials ≤24 h in duration measured EI only. Among the clinical trials >24 h in duration, EI was measured in 1 study (11.1%), fat mass and/or body fat percentage was measured in 3 studies (33.3%), and WC and/or W:H ratio was measured in 2 studies (22.2%). BW and/or BMI was measured in all longitudinal cohorts; EI (n = 2, 50.0%) and WC and/or W:H ratio (n = 1, 25.0%) was also measured in select cohorts. Only BW and/or BMI was reported in the

case–control study. Among the cross-sectional studies, BW and/or BMI, EI, and WC and/or W:H ratio, were reported in 18 (100%), 6 (33.3%), and 3 studies (16.7%), respectively.

Studies on other sweet intake

Study Design.

A total of 127 studies (15.8% of all included studies) investigated the association between other sweet dietary exposures and a BW-related outcome and/or EI. These studies included 49 clinical trials, 22 longitudinal cohorts, 50 cross-sectional studies, and 6 other study designs. The other sweet exposures included, but were not limited to, flavored/sweetened dairy products, fruit, fruit juices, chewing gum, and sweetness enhancers (e.g., miraculin).

Duration.

All clinical trials investigating other sweetness exposures were <0.5 y in duration, with the bulk of studies ($n = 36$) lasting ≤24 h. The longitudinal cohort studies ranged from 0.5 y to ≥10 y in duration, most frequently ranging from 1 to <5 y ($n = 8$). The other studies of other design were either 1 to <10 y in duration ($n = 4$) or cross-sectional ($n = 2$).

Methods to evaluate sweetness.

The sweetness of the exposure was measured in 10 clinical trials (20.4% of the clinical trials): 4 studies used VAS, 2 used categorical scales, 1 used a labeled magnitude scale, and 3 did not specify the method used to evaluate sweetness.

Outcomes.

EI was the most common outcome measured in clinical trials. It was the only outcome reported in clinical trials ≤24 h in duration and reported in 10 of the 13 clinical trials >24 h in duration. BW and/or BMI, fat mass and/or body fat percentage, and WC and/or W:H ratio was reported in 12 (92.3%), 9 (69.2%), and 6 (46.2%) clinical trials >24 h in duration. BW and/or BMI was most commonly reported in longitudinal cohorts ($n = 20$, 90.9%), cross-sectional studies ($n = 46$, 92.0%), and other study designs ($n = 6$, 100%). Fat mass and/or body fat percentage ($n = 1$, 4.5%; $n = 7$, 14.0%; $n = 0$, 0%; respectively) and WC and/or W:H ratio were also measured in select longitudinal cohorts, cross-sectional studies, and other study designs ($n = 5$, 22.7%; $n = 13$, 26%; $n = 2$, 33.3%; respectively).

Evidence Gaps

The heat maps of the number of studies identified by sweetness intervention/exposure and study design type for each BW-related outcome displayed in Figure 3 provide a graphical representation of the available evidence on dietary sweetness and BW-related outcomes. These heat maps were used to determine where evidence gaps exist.

Few studies ($n = 7$) investigated associations between total dietary sweetness and a BW-related outcome and/or EI, the primary interest of this scoping review. The bulk of the available evidence on sweetness exposures focuses on the intake of individual foods/beverages assumed to be sweet or the level of sugars or sweeteners. In addition, these studies were predominantly cross-sectional or short in duration (≤24 h) (34, 36–40) except for 1 clinical trial that studied sweetness exposures for 24 wk (35). More research investigating the association between total dietary sweetness and BW, particularly in the form of clinical trials and/or cohort trials of long duration, are needed in order to draw conclusions regarding the effect of dietary sweetness on BW.

Not only are there a limited number of studies that evaluated the sweetness of the total diet or individual foods/beverages, but there are many and variable methods used in the studies that do measure sweetness. Taste databases developed using a modified Spectrum ™ approach to determine the sensory attributes of different commonly consumed foods (36, 37, 39) allow for systematic evaluations of total dietary sweetness exposure. The taste databases developed to date are based on the foods consumed within a specific country, and thus are country-specific. Current databases are developed in Australia, France, Netherlands, and Malaysia; consideration of cuisines consumed in additional countries would be of value. Utilizing the currently available taste databases to determine associations between sweet taste exposure and BW status are important research priorities. Such taste databases may also be adapted for use in clinical trials to evaluate dietary sweetness, but direct measures of sweetness of the foods/beverages consumed within a diet by the specific study sample may be more applicable for clinical trials that have been specifically designed to measure the effect of differences in dietary sweetness on BW.

Discussion

The goal of this scoping review and evidence map was to summarize the published evidence on dietary sweetness exposure and BW-related outcomes and/or EI. Although 225 clinical trials and 383 observational studies have investigated intake of various dietary sources of sweetness on BW-related outcomes and/or EI, only 7 studies evaluated the sweetness of the entire diet (34–40). Among these 7 studies designed to compare high with low total dietary sweetness intake, there is little evidence to suggest that dietary sweetness is associated with BW and/or EI. In the 1 long-term clinical trial that exposed individuals to an isoenergetic high and low sweetness diet (35), no effect on BW or BMI were observed whereas beneficial changes to WC were observed among participants consuming the low sweetness diet compared with the high sweetness diet. In the 24 h clinical trial, no difference in ad libitum EI was observed between a predominantly sweet compared with predominantly savory or mixed diet (34). Among the cross-sectional studies and study using crowd-sourced data, individuals with overweight or obesity consumed less energy or similar amounts of energy from sweet tasting foods compared with normal weight individuals (36–40). Collectively, these results do not suggest that high dietary sweetness adversely affects BW, but further systematic evaluation of study quality and risk of bias of these studies is required.

The limited availability of evidence on total dietary sweetness may be due to the many challenges associated with determining the sweetness of the entire diet. Sweetness is a basic taste quality that can be measured in individual foods and beverages using a variety of methods (11). The sweetness of the diet, however, is determined by the source (e.g., sugars, LCS), intensity (e.g., concentration), food matrix (e.g., solid, semi-solid, liquid), amount (e.g., weight, volume), frequency (e.g., times/d), and duration (e.g., time/consumption event) of each individual dietary exposure. Therefore, the complex nature of the diet makes it difficult to characterize the taste of an entire diet. Although there is not a standardized method to determine total dietary sweetness (11), development of taste databases has made progress towards evaluating total dietary taste exposures. Taste databases have been developed based on food consumed in Australia (27), France (28), Netherlands (46), and Malaysia (46). The Australian and Dutch taste databases have been used to evaluate an association between total dietary sweetness exposure and BW at the time of the literature search (36, 37, 39). Since the search was conducted for the current review, a similar analysis (47) of the association between taste exposures, dietary intake, and BW was published utilizing the food consumption data from the follow-up Singapore Multi-Ethnic Cohort Phase 2 (MEC2) study in combination with the Dutch and Malaysian taste databases (46). Further utilization of currently available taste databases could address gaps in evidence regarding the association between total dietary sweetness and BW, but development of population-specific taste databases may be necessary to evaluate sweetness exposures in other population-level analyses.

The provision of sweetness with little to no energy, as can be achieved with LCS, further complicates the relation between sweetness exposure and BW. The focus of this review was total dietary sweetness, not specific sources of sweetness. However, LCS are unique from most sugars in that they contribute little to no energy, an important characteristic when BW and EI are the outcomes of interest. In addition, LCS are not just inert sweetness vehicles; they bind to taste 1 receptor member 2/taste 1 receptor member 3 (T1R2/T1R3) G-protein coupled sweet taste receptor heterodimer located throughout the gastrointestinal track, pancreas, and hypothalamus (48–50). Each LCS has a unique chemical structure, which influences how it binds to the T1R2/T1R3 heterodimer (51–53) and its metabolic fate (54); both of which may influence the post-ingestive effects of LCS intake. Recent systematic reviews of RCTs suggest that the substitution of sugar with LCS may be beneficial for BW (55–57), yet evidence from observational studies suggest LCS may have either no effect (58, 59) or adverse effects on BW indices (55, 58, 60). Although LCS may be a valuable tool to help reduce total sugar intake while maintaining dietary palatability, their post-ingestive effects may influence their efficacy for facilitating BW maintenance and should not be ignored.

Most of the studies identified that measured the sweetness of individual foods/beverages consumed within the diet were not designed to measure BW. These studies were predominantly laboratory-based interventions, acute in duration, and measured EI only. Laboratory-based interventions are tightly controlled and have a high degree of internal validity, but lack external validity due to other external factors that influence EI while free-living (61). Although long-term changes in energy balance may influence BW, intraindividual variation in daily EI deviates widely (62, 63), thus EI at a single meal or a single day is a poor predictor of BW. Longer term studies of usual EI, capturing day-to-day variations, are needed to provide additional insight regarding the chronic association between sweetness exposure and BW changes.

A product of this review was a database of published literature which is publicly available for use by the scientific community to further investigate this body of evidence and to highlight gaps in knowledge regarding dietary sweetness and BW (osf.io/my7pb). The search terms used to identify relevant publications were piloted to ensure relevant studies would be captured, a strength of this review. Yet, the search was restricted to publications in English, and some studies may have been missed because of different key terms used (e.g., studies where the sweetness exposure was also the outcome measurement; studies that assessed foods/beverages that were not conventionally considered sweet and provided insufficient information on the level of sweetness). Additionally, some excluded studies measured total dietary sweetness but did not meet at least 1 other component of the PI(E)COS criteria; in particular, studies that looked at dietary sweetness but did not report a BW-related outcome and studies that looked at sweet preference or sensitivity but not sweet taste exposure. For example, 1 cross-sectional study determined total dietary sweetness exposure based on 7 d of food records, and reported a correlation between the percent of calories from sweet foods with macronutrient composition of the diet, but did not report EI (64). Another study analyzed sweet preference (not sweet food/beverage intake) but otherwise met the inclusion criteria (65). Only published evidence was included in this evidence map and the authors were not contacted to obtain additional information. It is possible that some excluded studies may have relevant data that is either unpublished or published in papers that were not identified in the search.

This scoping review and evidence map identified evidence gaps in the published literature based primarily on study count and is not a critical appraisal of the available evidence. It is outside the scope of the scoping review/evidence map methodology to critically appraise study quality or risk of bias. The included evidence was ordered based on sweetness exposure and study design types, but no further judgments of study quality were made. This would be required before conclusions based on the evidence available can be drawn. In addition, quantitative analyses (e.g., meta-analyses) were not undertaken. There is no agreed upon minimum number of studies that are needed to conduct a quantitative meta-analysis (66); Cochrane states that $\geq$ 2 studies are needed, with the caveat that those studies should have similar methods and results that can be meaningfully pooled (67).

Although 7 studies (2 clinical trials, 4 cross-sectional studies, and 1 of other study design) assessed the association between total dietary sweetness and a BW-related outcome, further critical evaluation of this literature is necessary to determine if these studies can be systematically combined to quantify this association. The sweet exposures detailed in the studies included in the database were systematically categorized as either total dietary sweetness, sweet foods/beverages, sugar, sweetener, or other sweet exposure. However, some exposures could be categorized in multiple categories [e.g., high sucrose diets (sugar intake) achieved by adding SSB to the diet (sweet food/beverage intake)]. Although the hierarchy based on sweetness exposures used to classify the identified studies was appropriate for the current review, it may need to be adapted for subsequent analyses, depending on the research question. Further evaluation of the systematic reviews identified in this literature search was outside of the scope of the current review. A systematic review of the identified systematic reviews could help further understand the relation between sweetness interventions/exposures and BW-related outcomes.

The focus of this scoping review and evidence map was the effect of sweetness on BW. However, sweetness is only 1 dimension of taste and 1 component that determines the palatability of foods and the diet. Sweetness is rarely consumed in isolation from other sensory properties; it tends to cluster with sour (e.g., fruit, sweetened yogurt) or fat (e.g., pastry, cake, biscuits, ice cream) (36, 37). These other sensory properties also influence palatability (68). Thus, a high sweetness diet alone may not be prone to excess consumption, but instead a highly palatable diet, which may include sweetness, may influence food choice and BW (69). Other sensory properties and the palatability of the diet were not investigated in this evidence map but should be considered when exploring whether sensory properties of the diet influence dietary habits and BW.

In conclusion, although there is a breadth of evidence from studies that investigate sweet food/beverage, sugar, and sweetener intake and BW, there is limited evidence on the association between total dietary sweetness and BW. Utilization of the open access database of studies that have investigated associations between sweetness exposures and BW-related outcomes and/or EI developed as part of this evidence map can provide additional insights into this relation.

Data Sharing

Data described in the manuscript will be made publicly and freely available without restriction at https://osf.io/ckh9v/.

Acknowledgments

The authors' responsibilities were as follows—KAH, RR, DB, KA: designed research; KAH, RR, DB, KA: screened publications for inclusion; KAH, RR, DB, LEO, KA: completed the data extraction; KAH: analyzed data, wrote the paper with editorial assistance from all authors, had primary responsibility for final content; and all authors: read and approved the final manuscript.

References

1. WHO. [Internet] Guideline: sugars intake for adults and children. Geneva, WHO; 2015.
2. USDA. [Internet] Dietary guidelines for Americans, 2020–2025. 9th ed, 2020.
3. Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 2009;120(11):1011–20.
4. Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42(5):731–54. doi: 10.2337/dci19-0014.
5. EFSA NDA Panel (EFSA Panel on Nutrition NFaFA, Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Scientific opinion on the tolerable upper intake level for dietary sugars. EFSA J 2022;20(2):e07074.
6. Health Canada. Internet Canada's dietary guidelines for health professionals and policy makers. 2019. https://food-guide.canada.ca/en/guidelines/(accessed July 16, 2022).
7. Pan American Health Organization. Internet Pan American Health Organization Nutrient Profile Model. 2016. https://iris.paho.org/handle/10665.2/18621(accessed July 16, 2022).
8. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 2012;346(3):e7492. doi: 10.1136/bmj.e7492.
9. Appleton KM, Tuorila H, Bertenshaw EJ, de Graaf C, Mela DJ. Sweet taste exposure and the subsequent acceptance and preference for sweet taste in the diet: systematic review of the published literature. Am J Clin Nutr 2018;107(3):405–19.
10. Sørensen LB, Møller P, Flint A, Martens M, Raben A. Effect of sensory perception of foods on appetite and food intake: a review of studies on humans. Int J Obes 2003;27(10):1152–66. doi: 10.1038/sj.ijo.0802391.
11. Trumbo PR, Appleton KM, de Graaf K, Hayes JE, Baer DJ, Beauchamp GK, et al. Perspective: measuring sweetness in foods, beverages, and diets: toward understanding the role of sweetness in health. Adv Nutr 2021;12(2):343–54.
12. Cheon E, Reister EJ, Hunter SR, Mattes RD. Finding the sweet spot: measurement, modification, and application of sweet hedonics in humans. Adv Nutr 2021 12(6):2358–71.
13. Wise PM, Nattress L, Flammer LJ, Beauchamp GK. Reduced dietary intake of simple sugars alters perceived sweet taste intensity but not perceived pleasantness. Am J Clin Nutr 2016;103(1):50–60.
14. van Dongen MV, van den Berg MC, Vink N, Kok FJ, de Graaf C. Taste–nutrient relationships in commonly consumed foods. Br J Nutr 2012;108(1):140–7. doi: 10.1017/S0007114511005277.
15. van Langeveld AWB, Gibbons S, Koelliker Y, Civille GV, de Vries JHM, de Graaf C, et al. The relationship between taste and nutrient content in commercially available foods from the United States. Food Qual Preference 2017;57:1–7. https://doi.org/10.1016/j.foodqual.2016.10.012.
16. de Graaf C, Schreurs A, Blauw YH. Short-term effects of different amounts of sweet and nonsweet carbohydrates on satiety and energy intake. Physiol Behav 1993;54(5):833–43. doi: 10.1016/0031-9384(93)90290-v.
17. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z. (Editors). JBI manual for evidence synthesis, JBI, 2020. Available from https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-20-12.

18. Schmucker C, Motschall E, Antes G, Meerpohl JJ. Methods of evidence mapping. A systematic review. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2013;56(10):1390–7. doi: 10.1007/s00103-013-1818-y.
19. Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Syst Rev 2016;5:(1):28. doi: 10.1186/s13643-016-0204-x.
20. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169(7):467–73. doi: 10.7326/m18-0850.
21. Higgins K, Rawal R, Appleton K, Baer D. Evidence map on the relationship between exposure to dietary sweetness and body weight-related outcomes in adults. OSF; 2021. Internet: osf.io/my7pb(accessed August 2, 2021).
22. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman SD, Breckler SJ, et al. Transparency and Openness Promotion (TOP) guidelines. Internet OSF; 2021. osf.io/9f6gx(accessed July 16, 2022).
23. Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Saf 2008;31(3):199–215. doi: 10.2165/00002018-200831030-00002.
24. Henkin RI. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf 1994;11(5):318–77. doi: 10.2165/00002018-199411050-00004.
25. FDA. Internet Medications target long-term weight control. 2012. https://www.fda.gov/consumers/consumer-updates/medications-target-long-term-weight-control (accessed May 10, 2021).
26. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity. 2016. Internet: www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity (accessed May 10, 2021).
27. Lease H, Hendrie GA, Poelman AAM, Delahunty C, Cox DN. A sensory-diet database: a tool to characterise the sensory qualities of diets. Food Qual Preference 2016;49:20–32. doi: https://doi.org/10.1016/j.foodqual.2015.11.010.
28. Martin C, Visalli M, Lange C, Schlich P, Issanchou S. Creation of a food taste database using an in-home "taste" profile method. Food Qual Preference 2014;36:70–80. doi: https://doi.org/10.1016/j.foodqual.2014.03.005.
29. Teo PS, van Langeveld AWB, Pol K, Siebelink E, de Graaf C, Martin C, et al. Training of a Dutch and Malaysian sensory panel to assess intensities of basic tastes and fat sensation of commonly consumed foods. Food Qual Preference 2018;65:49–59. doi: https://doi.org/10.1016/j.foodqual.2017.11.011.
30. Yetley EA, MacFarlane AJ, Greene-Finestone LS, Garza C, Ard JD, Atkinson SA, et al. Options for basing dietary reference intakes (DRIs) on chronic disease endpoints: report from a joint US–Canadian-sponsored working group. Am J Clin Nutr 2017;105(1):249S–85S.
31. FDA.[Internet] Nutrition and supplement facts labels questions and answers related to the compliance date, added sugars, and declaration of quantitative amounts of vitamins and minerals: guidance for industry. Washington DC, FDA Center for Food Safety and Applied Nutrition; 2018.
32. Bowman SA, Clemens JC, Friday JE, Moshfegh AJ. Food patterns equivalents database 2017–2018: methodology and user guide. Food Surveys Research Group, Beltsville Human Nutrition Research Center, Agricultural Research Service, US Department of Agriculture; Beltsville, Maryland 2020. http://www.ars.usda.gov/nea/bhnrc/fsrg.
33. Higgins K, Rawal R, Baer D, O'Connor L, Appleton K. Internet Evidence map on the relationship between exposure to dietary sweetness and body weight-related outcomes in adults. OSF; 2022. osf.io/ckh9v(accessed July 20, 2022).
34. Griffioen-Roose S, Hogenkamp PS, Mars M, Finlayson G, de Graaf C. Taste of a 24-h diet and its effect on subsequent food preferences and satiety. Appetite 2012;59(1):1–8. doi: 10.1016/j.appet.2012.03.013.
35. Domínguez-Coello S, Carrillo-Fernández L, Gobierno-Hernández J, Méndez-Abad M, Borges-Álamo C, García-Dopico JA, et al. Decreased consumption of added fructose reduces waist circumference and blood glucose concentration in patients with overweight and obesity. The DISFRUTE study: a randomised trial in primary care. Nutrients 2020;12(4):1149. doi: 10.3390/nu12041149.
36. van Langeveld AWB, Teo PS, Mars M, Feskens EJM, de Graaf C, de Vries JHM. Evaluation of dietary taste patterns as assessed by FFQ against 24-h recalls and biomarkers of exposure. Eur J Clin Nutr 2019;73(1):132–40. doi: 10.1038/s41430-018-0300-1.
37. van Langeveld AWB, Teo PS, de Vries JHM, Feskens EJM, de Graaf C, Mars M. Dietary taste patterns by sex and weight status in the Netherlands. Br J Nutr 2018;119(10):1195–206. doi: 10.1017/s0007114518000715.
38. Cox DN, Perry L, Moore PB, Vallis L, Mela DJ. Sensory and hedonic associations with macronutrient and energy intakes of lean and obese consumers. Int J Obes 1999;23(4):403–10. doi: 10.1038/sj.ijo.0800836.
39. Cox DN, Hendrie GA, Lease HJ, Rebuli MA, Barnes M. How does fatty mouthfeel, saltiness or sweetness of diets contribute to dietary energy intake? Appetite 2018;131:36–43. doi: 10.1016/j.appet.2018.08.039.
40. Howell PD, Martin LD, Salehian H, Lee C, Eastman KM, Kim J. Analyzing taste preferences from crowdsourced food entries. Proceedings of the 6th International Conference on Digital Health Conference. 2016:131–40.
41. Dus C, Stapleton L, Trail A, Krogmann AR, Civille GV. Spectrum™ Method—descriptive analysis in sensory evaluation, New York, John Wiley and Sons; 2018. 319–53.
42. Griffioen-Roose S, Mars M, Finlayson G, Blundell JE, de Graaf C. Satiation due to equally palatable sweet and savory meals does not differ in normal weight young adults. J Nutr 2009;139(11):2093–98.
43. Borg P, Fogelholm M, Kukkonen-Harjula K. Food selection and eating behaviour during weight maintenance intervention and 2-y follow-up in obese men. Int J Obes 2004;28(12):1548–54. doi: 10.1038/sj.ijo.0802790.
44. Flack KD, Ufholz K, Casperson S, Jahns L, Johnson L, Roemmich JN. Decreasing the consumption of foods with sugar increases their reinforcing value: a potential barrier for dietary behavior change. J Acad Nutr Diet 2019;119(7):1099–108. https://doi.org/10.1016/j.jand.2018.12.016.
45. Ford HE, Peters V, Martin NM, Sleeth ML, Ghatei MA, Frost GS, et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. Eur J Clin Nutr 2011;65(4):508–13. doi: 10.1038/ejcn.2010.291.
46. Teo PS, van Langeveld AWB, Pol K, Siebelink E, de Graaf C, Yan SW, et al. Similar taste-nutrient relationships in commonly consumed Dutch and Malaysian foods. Appetite 2018;125:32–41. https://doi.org/10.1016/j.appet.2018.01.020.
47. Teo PS, Tso R, van Dam RM, Forde CG. Taste of modern diets: the impact of food processing on nutrient sensing and dietary energy intake. J Nutr 2022;152(1):200–10.
48. Fernstrom JD, Munger SD, Sclafani A, de Araujo IE, Roberts A, Molinary S. Mechanisms for sweetness. J Nutr 2012;142(6):1134S–41S.
49. Nakagawa Y, Nagasawa M, Yamada S, Hara A, Mogami H, Nikolaev VO, et al. Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion. PLoS One 2009;4(4):e5106. doi: 10.1371/journal.pone.0005106.
50. Ren X, Zhou L, Terwilliger R, Newton SS, de Araujo IE. Sweet taste signaling functions as a hypothalamic glucose sensor. Front Integr Neurosci 2009;3:12. doi: 10.3389/neuro.07.012.2009.
51. Nie Y, Vigues S, Hobbs JR, Conn GL, Munger SD. Distinct contributions of T1R2 and T1R3 taste receptor subunits to the detection of sweet stimuli. Curr Biol 2005;15(21):1948–52. doi: 10.1016/j.cub.2005.09.037.
52. Masuda K, Koizumi A, Nakajima K, Tanaka T, Abe K, Misaka T, et al. Characterization of the modes of binding between human sweet taste receptor and low-molecular-weight sweet compounds. PLoS One 2012;7(4):e35380. doi: 10.1371/journal.pone.0035380.

53. Kim S-K, Chen Y, Abrol R, Goddard WA, Guthrie B. Activation mechanism of the G protein-coupled sweet receptor heterodimer with sweeteners and allosteric agonists. Proc Natl Acad Sci 2017;114(10):2568–73. doi:10.1073/pnas.1700001114.
54. Magnuson BA, Carakostas MC, Moore NH, Poulos SP, Renwick AG. Biological fate of low-calorie sweeteners. Nutr Rev 2016;74(11):670–89. doi: 10.1093/nutrit/nuw032.
55. Rios-Leyvraz M, Montez J. Health effects of the use of non-sugar sweeteners: a systematic review and meta-analysis. Geneva, WHO; 2022. https://www.who.int/publications/i/item/9789240046429.
56. Rogers PJ, Appleton KM. The effects of low-calorie sweeteners on energy intake and body weight: a systematic review and meta-analyses of sustained intervention studies. Int J Obes 2021;45(3):464–78. doi: 10.1038/s41366-020-00704-2.
57. Laviada-Molina H, Molina-Segui F, Pérez-Gaxiola G, Cuello-García C, Arjona-Villicaña R, Espinosa-Marrón A, et al. Effects of nonnutritive sweeteners on body weight and BMI in diverse clinical contexts: systematic review and meta-analysis. Obes Rev 2020;21(7):e13020. doi: 10.1111/obr.13020.
58. Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. Am J Clin Nutr 2014;100(3):765–77.
59. Rogers PJ, Hogenkamp PS, de Graaf C, Higgs S, Lluch A, Ness AR, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes 2016;40(3):381–94. doi: 10.1038/ijo.2015.177.
60. Azad MB, Abou-Setta AM, Chauhan BF, Rabbani R, Lys J, Copstein L, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. Can Med Assoc J 2017;189(28):E929–39. doi: 10.1503/cmaj.161390.
61. Blundell J, De Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev 2010;11(3):251–70. https://doi.org/10.1111/j.1467-789X.2010.00714.x.
62. Basiotis PP, Welsh SO, Cronin FJ, Kelsay JL, Mertz W. Number of days of food intake records required to estimate individual and group nutrient intakes with defined confidence. J Nutr 1987;117(9):1638–41.
63. Champagne CM, Han H, Bajpeyi S, Rood J, Johnson WD, Lammi-Keefe CJ, et al. Day-to-day variation in food intake and energy expenditure in healthy women: the Dietitian II Study. J Acad NutrDiet 2013;113(11):1532–8. doi: 10.1016/j.jand.2013.07.001.
64. Mattes RD, Mela DJ. Relationships between and among selected measures of sweet-taste preference and dietary intake. Chem Senses 1986;11(4):523–39. doi: 10.1093/chemse/11.4.523.
65. Proserpio C, Laureati M, Bertoli S, Battezzati A, Pagliarini E. Determinants of obesity in Italian adults: the role of taste sensitivity, food liking, and food neophobia. Chem Senses 2016;41(2):169–76. doi: 10.1093/chemse/bjv072.
66. Valentine JC, Pigott TD, Rothstein HR. How many studies do you need?:A primer on statistical power for meta-analysis. JEBS 2010;35(2):215–47. doi: 10.3102/1076998609346961.
67. Ryan R, Cochrane Consumers and Communication Review Group. Cochrane Consumers and Communication Group: meta-analysis. 2016. Internet: http://cccrg.cochrane.org, (accessed July 16, 2022).
68. Drewnowski A. Energy intake and sensory properties of food. Am J Clin Nutr 1995;62(5):1081S–5S.
69. Johnson F, Wardle J. Variety, palatability, and obesity. Adv Nutr 2014;5(6):851–9.